In our pursuit to improve the lives of people living with cancer, Clovis Oncology is committed to realizing the promise of precision medicine for cancer.We seek to develop targeted therapies to better
Clovis Oncology: Pioneering Precision Medicine for Cancer Treatment
Clovis Oncology is a biopharmaceutical company that is dedicated to developing innovative cancer treatments. The company was founded in 2009 and has since been at the forefront of precision medicine, which involves tailoring treatments to individual patients based on their genetic makeup.
The mission of Clovis Oncology is to improve the lives of people living with cancer by realizing the promise of precision medicine. The company's focus is on developing targeted therapies that are designed to be more effective and less toxic than traditional chemotherapy.
One of Clovis Oncology's most promising drugs is Rubraca (rucaparib), which was approved by the FDA in 2016 for the treatment of ovarian cancer. Rubraca works by inhibiting an enzyme called PARP, which plays a key role in repairing damaged DNA. By blocking PARP, Rubraca can prevent cancer cells from repairing themselves and ultimately lead to their death.
In addition to Rubraca, Clovis Oncology has several other drugs in its pipeline that are being developed for various types of cancer. These include lucitanib, which targets multiple pathways involved in tumor growth and angiogenesis; FAP-2286, a peptide-targeted radionuclide therapy for solid tumors; and CLVS-601, a prodrug designed to selectively deliver chemotherapy directly into tumors.
Clovis Oncology's commitment to precision medicine extends beyond drug development. The company also offers diagnostic tests that can help identify patients who are most likely to benefit from its therapies. For example, its FoundationFocus CDxBRCA test can detect mutations in BRCA1/2 genes that make certain cancers more susceptible to PARP inhibitors like Rubraca.
In addition to its scientific achievements, Clovis Oncology has also been recognized for its commitment to corporate responsibility. The company has implemented sustainable practices throughout its operations and supports various charitable organizations focused on cancer research and patient advocacy.
Overall, Clovis Oncology is a leader in the field of precision medicine for cancer treatment. Its innovative therapies have already made a significant impact on patients' lives, and it continues to push forward with new developments that have the potential to revolutionize how we approach this devastating disease.